

Industry Advisory Board – Ribomed

Melissa J. Moore



Previously serving as a member of Moderna's Scientific Advisory Board, Dr. Moore became the CSO of the company's mRNA research platform in September 2016. She received many distinctions, which include National Academy of Science (2017), American Academy of Arts and Sciences (2019), 100 Fiercest Women in Biotech (2018) and PharmaVoice 100 (2019).

Dr. Moore graduated from the College of William and Mary in 1984 with a BS in Chemistry and Biology, and earned her PhD in Biological Chemistry from the Massachusetts Institute of Technology (MIT) in 1989. Following a Helen Hay Whitney Postdoctoral Fellowship at the MIT Center for Cancer Research, Dr. Moore joined the Brandeis University faculty in 1994. Before joining Moderna, she served as Professor at the University of Massachusetts Medical School, where she maintains her academic affiliation as a part-time faculty member. Dr. Moore was as a founding co-director of the RNA Therapeutics Institute and held the Eleanor Eustis Farrington Chair of Cancer Research. In 2011, Dr. Moore received the ASBMB William C. Rose Award for distinguished mentorship. She also served as an Investigator at the Howard Hughes Medical Institute (HHMI) during a nineteen-year run (1997-2016).

Adrian R. Krainer



Dr. Krainer is the co-founder and director of Stoke Therapeutics, a company leveraging groundbreaking work on RNA splicing. He is also the St. Giles Professor of Molecular Genetics and Program Chair of Cancer and Molecular Biology at Cold Spring Harbor Laboratory.

After completing a Bachelor of Arts degree in Biochemistry, in 1981, he earned a Doctor of Philosophy degree in Biochemistry from Harvard University, in 1986. Dr. Krainer is a member of the American Academy of Arts and Sciences, a Pew Scholar in the Biomedical Sciences and a recipient of an NIH MERIT award and New York Intellectual Property Law Association's 2017 Inventor of the Year. He won the 2019 Breakthrough Prize in Life Sciences and the 2019 RNA Society Lifetime Achievement Award, among other several honors, and was elected to the National Academy of Science in 2020.

Zandy Forbes



Dr. Alexandria Forbes is President and CEO of MeiraGTx, a clinical-stage gene therapy company. She received her M.A. in Natural Sciences from Cambridge University and her PhD in Molecular Genetics from Oxford University. Dr. Forbes was a research fellow at Duke University and also at the Carnegie Institute at Johns Hopkins University. After that, she was a research fellow at Duke University and at the Carnegie Institute at Johns Hopkins University. From March 1997 to September 2000, Dr. Forbes was a Human Frontiers/Howard Hughes postdoctoral fellow at the Skirball Institute of Biomolecular Medicine at NYU Langone Medical Center.

She then entered the hedge fund industry, spending eleven years as a healthcare investor at Sivik Global Healthcare, and almost 3 years at Meadowvale Asset Management. Dr. Forbes was a portfolio manager responsible for investments in biotechnology, specialty pharmaceuticals and diagnostics, and at Sivik/Argus Partners she managed the Global Life Science Fund, a long-biased fund focused on biotechnology. Prior to joining MeiraGTx, Dr. Forbes

served as Senior Vice President of Commercial Operations at Kadmon Holdings, a biopharmaceutical company, from September 2013 to April 2015 and currently serves as a member of its board of directors.

Keith Blundy



Since January 2017, Dr. Keith Blundy is the CEO of STORM Therapeutics, a company that focus on developing small molecule inhibitors of RNA-modifying enzymes for the treatment of cancer. Prior to STORM, in 1998, Dr. Keith joined Cancer Research Technology (CRT), the commercial arm of Cancer Research UK, and was Chief Operating Officer. From 2007, Dr. Keith took a new position as CEO of CRT, where he drove the development of CRT to become a global leader in the commercialization of cancer discoveries. He was instrumental in the launch of the 80M € Cancer Research Technology Pioneer Fund in partnership with the European Investment Fund (EIF) and BACIT, developed risk sharing drug discovery alliances with AstraZeneca, Teva (formerly Cephalon), Forma, Merck, and MRCT, negotiated the formation of the CRUK – Medimmune antibody therapeutics laboratory and developed CRT’s geographical reach through establishment of CRT Inc. in Boston (USA) and partnership with Cancer Therapeutics Pty in Melbourne, Australia.

Dr. Keith holds a BSc in Genetics from Leeds University and a PhD from the John Innes Institute. He undertook postdoctoral research in the US as a Fulbright Scholar on the regulation of plant gene expression. Dr. Keith also has an MBA from London Business School. He was formerly a director of KuDOS Pharmaceuticals, Mission Therapeutics and Cancer Therapeutics and is currently on the board of Inivata and chairman of Cizzle Biotech.